COLD + SINUS CAPLETS TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
03-02-2012
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
から入手可能:
VITA HEALTH PRODUCTS INC
ATCコード:
M01AE51
INN（国際名）:
IBUPROFEN, COMBINATIONS
投薬量:
200MG; 30MG
医薬品形態:
TABLET
構図:
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
投与経路:
ORAL
パッケージ内のユニット:
10/20
処方タイプ:
OTC
治療領域:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
製品概要:
Active ingredient group (AIG) number: 0222394001; AHFS:
認証ステータス:
APPROVED
承認日:
2006-10-17
製品の特徴
_ _
_Page 1 of 50_
PRODUCT MONOGRAPH
COLD + SINUS CAPLETS
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
USP
Analgesic/Antipyretic/Nasal Decongestant
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg, Manitoba
Canada, R2J 3W2
Control No. 151199
Date of Revision:
January 30, 2012
_ _
_ _
_Page 2 of 50_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
...............................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND
STABILITY..........................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................28
PART II: SCIENTIFIC INFORMATION
...............................................................................29
PHARMACEUTICAL
INFORMATION..........................................................................29
CLINICAL
TRIALS..........................................................................................................31
DETAILED
PHARMACOLOGY.....................................................................................33
TOXICOLOGY
.......
完全なドキュメントを読む
